非酒精性脂肪性肝病合并2型糖尿病患者血清铁蛋白变化及其临床意义

doi:10.3969/j.issn.1672-5069.2021.02.037

实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (2): 294-296.doi: 10.3969/j.issn.1672-5069.2021.02.037

非酒精性脂肪性肝病合并2型糖尿病患者血清铁蛋白变化及其临床意义

孙丽娜, 顾静

214065 江苏省无锡市华东疗养院老年病科

收稿日期:2020-09-10 出版日期:2021-03-10 发布日期:2021-04-30
通讯作者: 顾静,E-mail:g950324@163,com
作者简介:孙丽娜,女,硕士研究生,主治医师。E-mail:selina_sln@126.com
基金资助:
华东疗养院院内科研基金资助项目(编号:201802)

Serum ferritin levels in patients withnon-alcoholic fatty liver disease and type 2 diabetes mellitus

SUN Lina, Gu Jing

Department of Gastroenterology, Huadong Sanatorium, Wuxi 214065, Jiangsu Province, China

Received:2020-09-10 Online:2021-03-10 Published:2021-04-30

摘要/Abstract

摘要： 目的探讨非酒精性脂肪性肝病(NAFLD)合并2型糖尿病(T2DM)患者血清铁蛋白(SF)的变化及其临床意义。方法本文纳入633例NAFLD合并T2DM、163例T2DM和163例NAFLD患者,检测血清SF和其他血清指标,应用二分类Logistic多元回归分析。结果 NAFLD合并T2DM患者血清SF水平为(293.5±206.4)ng/ml,显著高于T2DM组[(122.1±108.8)ng/ml,P<0.01]或NAFLD组[(202.5±127.6)ng/ml,P<0.01];血清尿酸(UA)水平为(401.2±91.5)μmol/l,显著高于T2DM组[(345.7±88.227)μmol/l,P<0.01];血清C反应蛋白(CRP)水平为(2.4±1.9)mg/dl,显著高于T2DM组[(1.3±1.7)mg/dl,P<0.01]或NAFLD组[(1.6±1.4)mg/dl,P<0.01];二分类Logistic多元回归分析显示SF和UA是NAFLD合并T2DM的独立预测因素(P＜0.05)。结论检测血清铁可以预测NAFLD患者合并2型糖尿病,应该及时进行相关检查,以早期发现和处理。

关键词: 非酒精性脂肪性肝病, 2型糖尿病, 血清铁蛋白

Key words: Non-alcoholic fatty liver diseases, Type 2 diabetes mellitus, Ferritin

孙丽娜, 顾静. 非酒精性脂肪性肝病合并2型糖尿病患者血清铁蛋白变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(2): 294-296.

SUN Lina, Gu Jing. Serum ferritin levels in patients withnon-alcoholic fatty liver disease and type 2 diabetes mellitus[J]. Journal of Practical Hepatology, 2021, 24(2): 294-296.

参考文献

[1] Lade A, Noon L A, Friedman S L. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol, 2014, 26(1):100-107.
[2] Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol, 2019, 71(4):793-801.
[3] Datz C, Muller E, Aigner E. Iron overload and non-alcoholic fatty liver disease. Minerva Endocrinol, 2017, 42(2):173-183.
[4] 中华医学会内分泌学分会. 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版). 中华内分泌代谢杂志, 2018, 34(7):549-554.
[5] Sumida Y, Yoneda M, Hyogo H, et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol, 2011, 46(2):257-268.
[6] Kim CW, Chang Y, Sung E, et al. Serum ferritin levels predict incident non-alcoholic fatty liver disease in healthy Korean men. Metabolism, 2012, 61(8):1182-1188.
[7] Carmen GY, Victor SM. Signalling mechanisms regulating lipolysis. Cell Signal, 2006, 18(4):401-408.
[8] Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol, 2013, 10(6):330-344.
[9] Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med, 2012, 52(1):59-69.
[10] Mateo-Gallego R, Calmarza P, Jarauta E, et al. Serum ferritin is a major determinant of lipid phenotype in familial combined hyperlipidemia and familial hypertriglyceridemia. Metabolism, 2010, 59(2):154-158.
[11] Oshaug A, Bugge KH, Bjonnes C H, et al. Associations between serum ferritin and cardiovascular risk factors in healthy young men. a cross sectional study. Eur J Clin Nutr, 1995, 49(6):430-438.
[12] Ellidag HY, Eren E, Akdag M, et al. The relationship between serum ferritin levels and serum lipids and HDL function with respect to age and gender. Ukr Biochem J, 2016, 88(6):76-86.
[13] Corradini E, Meynard D, Wu Q, et al. Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology, 2011, 54(1):273-284.
[14] Ryu S, Chang Y, Kim SG, et al. Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. Metabolism, 2011, 60(6):860-866.
[15] Liu Z, Que S, Zhou L, et al. Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence: a meta-analysis of prospective studies. Sci Rep, 2015, 5:14325.
[16] Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care, 2009, 32(9):1737-1742.

非酒精性脂肪性肝病合并2型糖尿病患者血清铁蛋白变化及其临床意义

Serum ferritin levels in patients withnon-alcoholic fatty liver disease and type 2 diabetes mellitus

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈熙, 王玮, 高健伟, 许乐. 合并非酒精性脂肪性肝病对恩替卡韦治疗慢性乙型肝炎患者抗病毒疗效的影响[J]. 实用肝脏病杂志, 2021, 24(3): 343-346.
[2]	郝肖伟, 白娜, 郭小军, 陈永刚. 慢性丙型肝炎合并非酒精性脂肪性肝病患者血清A-FABP水平变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(3): 347-350.
[3]	贾群玲, 徐志宾, 韩舒. 非酒精性脂肪性肝病患者磁共振质子密度脂肪分数变化[J]. 实用肝脏病杂志, 2021, 24(3): 359-362.
[4]	刘翔鸷, 刘振显, 王晓燕. 中老年非酒精性脂肪性肝病患者胆石症与代谢危险因素关系探讨[J]. 实用肝脏病杂志, 2021, 24(3): 363-366.
[5]	晋颖, 周卫真, 冯世兵, 汪湃. 颅内出血患者合并非酒精性脂肪性肝病情况分析[J]. 实用肝脏病杂志, 2021, 24(3): 367-370.
[6]	王松姣, 张宇晨, 龚国富, 王宇学. 慢性乙型肝炎合并非酒精性脂肪性肝病患者血清反应性氧化物和脂联素水平变化[J]. 实用肝脏病杂志, 2021, 24(2): 204-207.
[7]	许磊磊, 许冠英, 江凯, 鲍亚星. 不同中医辨证分型NAFLD患者CT影像学特点分析[J]. 实用肝脏病杂志, 2021, 24(2): 216-219.
[8]	张彦, 夏文芳, 金进, 王黎. 利格列汀联合门冬胰岛素50治疗肝源性糖尿病患者疗效及HOMA-IR和HOMA-β水平变化[J]. 实用肝脏病杂志, 2021, 24(2): 240-243.
[9]	吴伟杰, 丁雯瑾, 范建高. 空气污染物PM2.5与非酒精性脂肪性肝病发病研究进展[J]. 实用肝脏病杂志, 2021, 24(2): 297-300.
[10]	荣爱梅, 张超, 吴慧丽. 西罗莫司对高脂饮食诱导的NAFLD大鼠外周血Treg/Th17细胞的影响[J]. 实用肝脏病杂志, 2021, 24(1): 10-13.
[11]	陈光榆, 王鸿, 王耀晟, 张熙, 张伟, 曾静, 沈峰, 胡颖, 范建高. 非酒精性脂肪性肝病患者血红蛋白水平变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(1): 39-42.
[12]	夏淑晶, 张莉莉, 张秀梅, 赵根宝, 周松伟, 罗欲承, 陈红芹, 王子华, 成凤干, 范建高. 非酒精性脂肪性肝病患者血清SDC4变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(1): 43-46.
[13]	魏秀琴, 闫晓霞, 石国荣, 赵宏伟, 李基寿. 阿托伐他汀联合硫普罗宁治疗非酒精性脂肪性肝病患者疗效初步研究[J]. 实用肝脏病杂志, 2021, 24(1): 47-50.
[14]	梁小丽, 邝继孙, 刘秋莉, 符弟. 非诺贝特联合热量限制饮食治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 51-54.
[15]	赵晓春, 钟庆, 刘书宏, 梁尘格, 郭熙清, 温林. 非酒精性脂肪性肝病并发2型糖尿病患者血尿酸水平变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(1): 55-58.